AIVITA Biomedical nabs $25m

AIVITA Biomedical Inc, a developer of personalized vaccines for the treatment of cancer and prevention of COVID-19, has raised up to $25 million in Series B-2 financing.

4 January 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles